Altimmune, Inc. (ALT) vs CytomX Therapeutics, Inc. (CTMX)
Altimmune, Inc. and CytomX Therapeutics, Inc. are both Biotechnology companies. Altimmune, Inc. and CytomX Therapeutics, Inc. are of similar size ($599.2M and $593.3M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against −87.0%. Altimmune, Inc. has the higher net margin (0.00% vs −451.6%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 17 metrics below, Altimmune, Inc. leads on 11 and CytomX Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | ALT | CTMX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (476.19%) | 0.00% |
| Net margin | 0.00% | (451.62%) | 0.00% |
| Free cash flow margin | 0.00% | (450.27%) | 0.00% |
| Return on equity | (28.87%) | (39.18%) | (57.72%) |
| Return on assets | (25.58%) | (29.72%) | (49.22%) |
| Return on invested capital | (34.30%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack